

# Insulin Glargine Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 42873-00025      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2015

---

## SECTION 1: IDENTIFICATION

Product name : Insulin Glargine Formulation

### Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd  
Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

## SECTION 2. HAZARDS IDENTIFICATION

### GHS Classification

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Nervous system)

### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.  
H318 Causes serious eye damage.  
H373 May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

P280 Wear protective gloves/ eye protection/ face protection.

### Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P314 Get medical advice/ attention if you feel unwell.

P332 + P313 If skin irritation occurs: Get medical advice/ attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Insulin Glargine	160337-95-1	$\geq 60$ - $\leq 100$
m-Cresol	108-39-4	$\geq 3$ - $< 5$

## SECTION 4. FIRST AID MEASURES

- |                         |   |  |
|-------------------------|---|--|
| General advice          | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.   |
| If inhaled              | : | If inhaled, remove to fresh air.<br>Get medical attention if symptoms occur.   |
| In case of skin contact | : | In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact  | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention immediately.   |
| If swallowed            | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.  |

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

Most important symptoms and effects, both acute and delayed	:	Rinse mouth thoroughly with water. Causes skin irritation. Causes serious eye damage. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

---

### SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are re-

## Insulin Glargine Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 42873-00025      Date of last issue: 04.04.2023  
 Date of first issue: 07.01.2015

leased into the atmosphere in sufficient concentration.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe dust.  
 Do not swallow.  
 Do not get in eyes.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.
- Conditions for safe storage : Keep in properly labelled containers.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Insulin Glargine	160337-95-1	TWA	3 µg/m <sup>3</sup> (OEB 4)	Internal
m-Cresol	108-39-4	TWA	5 ppm 22 mg/m <sup>3</sup>	AU OEL

## Insulin Glargine Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 42873-00025      Date of last issue: 04.04.2023  
 Date of first issue: 07.01.2015

Further information: Skin absorption				
		TWA (Inhalable fraction and vapor)	20 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Combined particulates and organic vapour type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection** : Wear the following personal protective equipment: Chemical resistant goggles must be worn. If splashes are likely to occur, wear: Face-shield

**Skin and body protection** : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance** : Crystalline powder

**Colour** : white

**Odour** : No data available

**Odour Threshold** : No data available

**pH** : No data available

**Insulin Glargine Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.

**Insulin Glargine Formulation**

Version 5.1      Revision Date: 30.09.2023      SDS Number: 42873-00025      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2015

---

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****Insulin Glargine:**

Acute oral toxicity : Remarks: No data available

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**m-Cresol:**

Acute oral toxicity : LD50 (Rat): 121 mg/kg  
Remarks: Based on data from similar materials

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Acute dermal toxicity : LD50 (Rabbit): 301 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****Insulin Glargine:**

**Insulin Glargine Formulation**

Version 5.1      Revision Date: 30.09.2023      SDS Number: 42873-00025      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2015

---

Remarks : No data available

**m-Cresol:**

Species : Rabbit  
Result : Corrosive after 3 minutes to 1 hour of exposure

**Serious eye damage/eye irritation**

Causes serious eye damage.

**Components:****Insulin Glargine:**

Remarks : No data available

**m-Cresol:**

Species : Rabbit  
Result : Irreversible effects on the eye

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Insulin Glargine:**

Remarks : No data available

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Insulin Glargine:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Result: negative  
Remarks: Based on data from similar materials



**Insulin Glargine Formulation**

Version 5.1      Revision Date: 30.09.2023      SDS Number: 42873-00025      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2015

---

**m-Cresol:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Ingestion  
Method: OECD Test Guideline 475  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Insulin Glargine:**

Species : Rat  
Exposure time : 2 Years  
NOAEL : 0.455 mg/kg body weight  
Result : negative

Species : Mouse  
Exposure time : 2 Years  
NOAEL : 0.455 mg/kg body weight  
Result : negative

**m-Cresol:**

Species : Mouse, males  
Application Route : Ingestion  
Exposure time : 105 weeks  
Result : equivocal  
Remarks : Based on data from similar materials

Species : Mouse, female  
Application Route : Ingestion  
Exposure time : 106 - 107 weeks  
Result : positive  
Remarks : Based on data from similar materials

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

**Reproductive toxicity**

Not classified based on available information.

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

### Components:

#### **Insulin Glargine:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0.36 mg/kg body weight Result: No effects on fertility  Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Subcutaneous Fertility: NOAEL: 0.072 mg/kg body weight Result: No effects on fertility
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Developmental Toxicity: NOAEL: 0.36 mg/kg body weight Result: No effects on foetal development  Species: Rabbit Application Route: Subcutaneous Developmental Toxicity: LOAEL: 0.072 mg/kg body weight Result: Fetotoxicity Remarks: The mechanism or mode of action may not be relevant in humans.

#### **m-Cresol:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	:	Test Type: Prenatal development toxicity study (teratogenicity) Species: Rat Application Route: Ingestion Result: negative

#### **STOT - single exposure**

Not classified based on available information.

#### **STOT - repeated exposure**

May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

### Components:

#### **Insulin Glargine:**

Exposure routes	:	Ingestion
Target Organs	:	Blood, Nervous system
Assessment	:	May cause damage to organs through prolonged or repeated

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

exposure.

### Repeated dose toxicity

#### Components:

##### Insulin Glargine:

Species	: Rat
NOAEL	: 0.5 mg/kg
LOAEL	: 1.5 mg/kg
Application Route	: Subcutaneous
Exposure time	: 30 d
Target Organs	: Blood, Nervous system

##### m-Cresol:

Species	: Rat
NOAEL	: 150 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks
Method	: OECD Test Guideline 408

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Insulin Glargine:

Inhalation	: Target Organs: Blood Symptoms: Hypoglycemia, Headache, Sweating, Tremors, Nausea
------------	---

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### m-Cresol:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 8.6 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia pulex (Water flea)): > 99.5 mg/l Exposure time: 48 h
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 1.35 mg/l Exposure time: 32 d Remarks: Based on data from similar materials
Toxicity to daphnia and other	: NOEC (Daphnia magna (Water flea)): 1 mg/l

**Insulin Glargine Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

aquatic invertebrates (Chronic toxicity)      Exposure time: 21 d  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****m-Cresol:**

Biodegradability      :    Result: Readily biodegradable.  
Biodegradation: 90 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301D

**Bioaccumulative potential****Components:****m-Cresol:**

Bioaccumulation      :    Species: Leuciscus idus (Golden orfe)  
Bioconcentration factor (BCF): 17 - 20

Partition coefficient: n-octanol/water      :    log Pow: 1.96

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues      :    Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging      :    Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number      :    Not applicable  
Proper shipping name      :    Not applicable  
Class      :    Not applicable  
Subsidiary risk      :    Not applicable  
Packing group      :    Not applicable  
Labels      :    Not applicable

**IATA-DGR**

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

UN/ID No. : Not applicable  
 Proper shipping name : Not applicable  
 Class : Not applicable  
 Subsidiary risk : Not applicable  
 Packing group : Not applicable  
 Labels : Not applicable  
 Packing instruction (cargo aircraft) : Not applicable  
 Packing instruction (passenger aircraft) : Not applicable

### IMDG-Code

UN number : Not applicable  
 Proper shipping name : Not applicable  
 Class : Not applicable  
 Subsidiary risk : Not applicable  
 Packing group : Not applicable  
 Labels : Not applicable  
 EmS Code : Not applicable  
 Marine pollutant : Not applicable

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### ADG

UN number : Not applicable  
 Proper shipping name : Not applicable  
 Class : Not applicable  
 Subsidiary risk : Not applicable  
 Packing group : Not applicable  
 Labels : Not applicable  
 Hazchem Code : Not applicable

### Special precautions for user

Not applicable

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

### The components of this product are reported in the following inventories:

AICS : not determined

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

DSL : not determined

IECSC : not determined

---

### SECTION 16: ANY OTHER RELEVANT INFORMATION

#### Further information

Revision Date : 30.09.2023  
 Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average  
 AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-

## Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	42873-00025	Date of first issue: 07.01.2015

---

recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN